LXEO News

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement